Cellworks CBM Biosimulation Identifies Genomic Causes for Induction Failure in AML Patients and Suggests Alternative Therapies

NEXT STORY
Autolus Therapeutics presents additional data on AUTO3 in DLBCL during the 62nd ASH Annual Meeting
PREV STORY
TG Therapeutics Announces Pivotal Data from the UNITY-CLL and UNITY-NHL Clinical Trials Presented at the 62nd American Society of Hematology Annual Meeting
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Enzymatica completes acquisition of Zymetech and includes new board members and representative to the nomination committee

Enzymatica AB (publ) ("Enzymatica") has today completed the acqusition of Zymetech and taken ownership ...

author_avatar
NASDAQ Market News

Thetis Builds Scientific Advisory Board to Guide Development of Immuno-Resolving Therapies for IBD

BRANFORD, Conn., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Thetis Pharmaceuticals LLC (“Thetis”), a biopharmaceutical ...

author_avatar
NASDAQ Market News

China Molecular Diagnostics Market, 2022 – Test Volume & Forecasts

Dublin, Sept. 13, 2017 (GLOBE NEWSWIRE) -- The "China Molecular Diagnostics Market, Test Volume ...

author_avatar
NASDAQ Market News